Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15359115rdf:typepubmed:Citationlld:pubmed
pubmed-article:15359115lifeskim:mentionsumls-concept:C0237401lld:lifeskim
pubmed-article:15359115lifeskim:mentionsumls-concept:C0040555lld:lifeskim
pubmed-article:15359115lifeskim:mentionsumls-concept:C0206515lld:lifeskim
pubmed-article:15359115lifeskim:mentionsumls-concept:C0003261lld:lifeskim
pubmed-article:15359115lifeskim:mentionsumls-concept:C0011155lld:lifeskim
pubmed-article:15359115lifeskim:mentionsumls-concept:C0445604lld:lifeskim
pubmed-article:15359115lifeskim:mentionsumls-concept:C0020859lld:lifeskim
pubmed-article:15359115lifeskim:mentionsumls-concept:C1977484lld:lifeskim
pubmed-article:15359115pubmed:issue5lld:pubmed
pubmed-article:15359115pubmed:dateCreated2004-9-10lld:pubmed
pubmed-article:15359115pubmed:abstractTextSearching for a possible explanation for the phenotypic heterogeneity in IgG3 deficiency, we studied the antibody response to a polysaccharide and a protein antigen in IgG3-deficient (IgG3d) adults after vaccination with Haemophilus influenzae type b capsular polysaccharide (Hib CP) conjugated to tetanus toxoid. Distribution of isotypes, idiotypes, clonotypes, and Gm allotypes were compared. All the vaccinated individuals, irrespective of the level of IgG3 and proneness to infections, developed protective levels of anti-Hib CP. Significantly lower prevaccination levels of IgG2 (p < 0.05) and IgG4 anti-Hib CP (p < 0.04 and p < 0.03) were noted among the infection-prone compared to the healthy IgG3d individuals and/or controls. Seventy percent of the IgG3d patients and none of the controls had the low responding Gm(ga-n/ga-n) genotype, while the majority of the controls had the alternative Gm(bfn/bfn) genotype. The conjugate ACT-HIB vaccine efficiently overcomes the IgG3 subclass deficiency state and the genetic predisposition for lower responsiveness, providing protection against Hib and tetanus infections. The proneness to infection in some IgG3d individuals may relate to their low prevaccination antibody levels.lld:pubmed
pubmed-article:15359115pubmed:languageenglld:pubmed
pubmed-article:15359115pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15359115pubmed:citationSubsetIMlld:pubmed
pubmed-article:15359115pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15359115pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15359115pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15359115pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15359115pubmed:statusMEDLINElld:pubmed
pubmed-article:15359115pubmed:monthSeplld:pubmed
pubmed-article:15359115pubmed:issn0271-9142lld:pubmed
pubmed-article:15359115pubmed:authorpubmed-author:HansonL ALAlld:pubmed
pubmed-article:15359115pubmed:authorpubmed-author:LucasAAlld:pubmed
pubmed-article:15359115pubmed:authorpubmed-author:OxeliusV AVAlld:pubmed
pubmed-article:15359115pubmed:authorpubmed-author:BjörkanderJJlld:pubmed
pubmed-article:15359115pubmed:authorpubmed-author:Hahn-ZoricMMlld:pubmed
pubmed-article:15359115pubmed:authorpubmed-author:FrimanVVlld:pubmed
pubmed-article:15359115pubmed:authorpubmed-author:UlanovaMMlld:pubmed
pubmed-article:15359115pubmed:issnTypePrintlld:pubmed
pubmed-article:15359115pubmed:volume24lld:pubmed
pubmed-article:15359115pubmed:ownerNLMlld:pubmed
pubmed-article:15359115pubmed:authorsCompleteYlld:pubmed
pubmed-article:15359115pubmed:pagination561-70lld:pubmed
pubmed-article:15359115pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:15359115pubmed:meshHeadingpubmed-meshheading:15359115...lld:pubmed
pubmed-article:15359115pubmed:meshHeadingpubmed-meshheading:15359115...lld:pubmed
pubmed-article:15359115pubmed:meshHeadingpubmed-meshheading:15359115...lld:pubmed
pubmed-article:15359115pubmed:meshHeadingpubmed-meshheading:15359115...lld:pubmed
pubmed-article:15359115pubmed:meshHeadingpubmed-meshheading:15359115...lld:pubmed
pubmed-article:15359115pubmed:meshHeadingpubmed-meshheading:15359115...lld:pubmed
pubmed-article:15359115pubmed:meshHeadingpubmed-meshheading:15359115...lld:pubmed
pubmed-article:15359115pubmed:meshHeadingpubmed-meshheading:15359115...lld:pubmed
pubmed-article:15359115pubmed:meshHeadingpubmed-meshheading:15359115...lld:pubmed
pubmed-article:15359115pubmed:year2004lld:pubmed
pubmed-article:15359115pubmed:articleTitleAntibody response to the Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in healthy and infection-prone individuals with IgG3 subclass deficiency.lld:pubmed
pubmed-article:15359115pubmed:affiliationDepartment of Clinical Immunology, University of Göteborg, S-413 46 Göteborg, Sweden. mirjana.hahn-zoric@immuno.gu.selld:pubmed
pubmed-article:15359115pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15359115pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15359115lld:pubmed